ALS Management: Diagnosis and Multidisciplinary Care Guide
Clinical Practice Update — Diagnosis, Disease-Modifying Therapy, Respiratory and Nutritional Support in Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based ALS management: diagnostic workup, disease-modifying therapy, gene-targeted treatment, multidisciplinary clinic care, and advance planning in adults
- Target Audience
- Neurologists, primary care physicians, palliative care teams, respiratory and rehabilitation specialists, residents
- Setting
- Specialist ALS clinics, general neurology, primary care, home-based care, hospice and palliative services
- Source Evidence
- •EFNS Guidelines on the Clinical Management of ALS (Andersen et al., 2012)
- •AAN Practice Parameter — Care of the Patient with ALS (Miller et al., 2009)
- •Awaji Electrodiagnostic Criteria (de Carvalho et al., Clin Neurophysiol 2008)
- •MCI-186 Trial — Edaravone in ALS (Lancet Neurology, 2017)
- •VALOR Trial — Tofersen for SOD1-ALS (NEJM, 2022)
Key Clinical Takeaways
Effective ALS management hinges on three overlapping priorities: confirm the diagnosis early, connect the patient to a specialist multidisciplinary clinic, and layer disease-modifying, symptomatic, and supportive care proactively. Multidisciplinary care extends survival by 6–12 months on average and improves quality of life across every measurable domain. The takeaways below distill contemporary evidence into bedside rules.
- 1Diagnose ALS using a combination of the clinical picture, updated El Escorial framework, and supportive electrodiagnostic findings → Diagnosis
- 2Apply the Awaji-shima criteria for EMG interpretation — fasciculations in a muscle with chronic neurogenic changes count as acute denervation → Diagnosis
- 3Refer every newly diagnosed patient to a specialist ALS multidisciplinary clinic — the single highest-yield intervention in ALS management → Multidisciplinary Care
- 4Start riluzole 50 mg twice daily as soon as the diagnosis is secure — the only disease-modifying therapy with robust survival evidence across populations → Disease-Modifying Therapy
- 5Offer genetic counselling and testing in every patient — not just familial cases — as gene-targeted therapies now exist for SOD1 → Gene-Targeted Therapy
- 6Monitor respiratory function every 3 months with FVC, SNIP, and overnight oximetry — initiate non-invasive ventilation early → Respiratory Care
- 7Offer gastrostomy before weight loss exceeds 10% of baseline and while FVC remains above 50% — timing is critical for safety → Nutritional Support
- 8Integrate palliative care from the start, not at the end — advance care planning is an ongoing conversation, not a single event → Palliative Care
- 9Screen for cognitive and behavioural changes — frontotemporal features occur in a substantial minority and affect decision-making capacity → Symptom Management
Diagnosing ALS: Clinical Criteria
ALS is a progressive neurodegenerative disorder characterised by combined upper and lower motor neuron involvement, progressive spread across regions (bulbar, cervical, thoracic, lumbosacral), and absence of an alternative explanation. Median time from symptom onset to diagnosis is still 10–16 months in most populations — an interval contemporary practice aims to shorten.
Diagnostic frameworks include the revised El Escorial criteria and the Awaji-shima electrodiagnostic modifications. The more recent Gold Coast criteria simplify the framework and improve sensitivity, particularly early in disease. Whichever framework is used, the diagnosis rests on the clinical pattern first.
Document upper motor neuron signs (hyperreflexia, spasticity, Hoffmann, Babinski) and lower motor neuron signs (weakness, wasting, fasciculations) in each of the four body regions. Progression to additional regions is the clinical hallmark of ALS.
Strong Rec High Evidence EFNS 2012 AAN 2009Actively exclude ALS mimics before committing to the diagnosis — cervical spondylotic myelopathy with radiculopathy, multifocal motor neuropathy with conduction block, inclusion body myositis, Kennedy disease, and paraneoplastic motor neuronopathy are the most important.
Strong Rec Moderate Evidence EFNS 2012Perform EMG and nerve conduction studies to support the diagnosis and detect subclinical denervation. Interpret findings using the Awaji-shima criteria — fasciculation potentials in a muscle with chronic neurogenic changes are diagnostically equivalent to acute denervation.
Strong Rec Moderate Evidence Awaji 2008 EFNS 2012Obtain MRI of the neuraxis involved in the clinical presentation to exclude structural mimics. Routine laboratory screening should include CK, thyroid function, vitamin B12, serum protein electrophoresis, and HIV serology when exposure is plausible.
Strong Rec Low Evidence EFNS 2012Disease-Modifying Therapy in ALS Management
Disease-modifying therapy in ALS management remains incremental but meaningful. Riluzole is the long-standing cornerstone, with edaravone and tofersen offering additional options in specific contexts. Even modest survival gains matter when combined with the larger effect of multidisciplinary care.
Start riluzole 50 mg orally twice daily as soon as the diagnosis is confirmed. Verify liver function monitoring at baseline and then monthly for the first 3 months, quarterly for the remainder of the first year, and periodically thereafter.
Strong Rec High Evidence EFNS 2012 AAN 2009Counsel patients on the magnitude of riluzole’s effect — an average survival gain of roughly 2–3 months in randomised trials, with larger real-world benefit suggested by registry data. Transparent communication of the expected benefit preserves trust.
Strong Rec Low Evidence EFNS 2012Consider edaravone (IV 60 mg daily on a cyclical schedule, or the oral suspension formulation) in carefully selected patients with early disease, preserved respiratory function, and rapid functional decline. Benefit is modest and restricted to a narrow pheno-genotype; discuss trade-offs of burden and cost with every patient.
Conditional Rec Moderate Evidence MCI-186 2017Do not start unproven or off-label disease-modifying agents outside of clinical trials. Actively facilitate enrolment in trials instead — participation is a concrete way to expand options for patients now and for the broader ALS community in the future.
Against Low Evidence EFNS 2012Disease-Modifying Agents at a Glance
| Drug | Typical Dose and Route | Best Suited For | Practical Tips and Pitfalls |
|---|---|---|---|
| Riluzole | 50 mg orally twice daily (tablet or oral suspension) | Every patient across the full disease trajectory | Monitor ALT/AST monthly x3, then quarterly. Consider oral suspension once swallowing declines. |
| Edaravone (IV) | 60 mg IV daily; 14-day cycles with drug-free intervals | Early, rapidly progressing disease with preserved FVC | High administration burden. Requires vascular access for extended periods. |
| Edaravone (oral suspension) | 105 mg daily in cycles matching the IV schedule | Patients who would benefit from edaravone but wish to avoid IV access | Take on an empty stomach, fast for 1 hour afterwards. Watch for sulphite hypersensitivity. |
| Tofersen | 100 mg intrathecal; 3 loading doses followed by monthly maintenance | SOD1-positive ALS confirmed on genetic testing | Requires neurofilament monitoring. Confirm SOD1 pathogenic variant before starting. |
Gene-Targeted Therapy for SOD1-ALS
Tofersen, an antisense oligonucleotide targeting SOD1 messenger RNA, has opened the gene-targeted era in ALS. In the VALOR trial and open-label extension, tofersen reduced neurofilament light chain and slowed functional decline in patients with SOD1-positive ALS. Approximately 2% of ALS is SOD1-related — small in proportion but meaningful to those affected.
Offer genetic counselling and testing to every patient with ALS — not only those with a family history. Contemporary yields identify a pathogenic variant in roughly 10–15% of apparently sporadic cases; SOD1 and C9orf72 are the most commonly implicated genes.
Strong Rec Moderate Evidence ICG MG Update 2020Initiate tofersen 100 mg intrathecally in patients with a confirmed pathogenic SOD1 variant, following regulatory and institutional protocols. Deliver the drug only in a specialist centre with neurofilament light chain monitoring and access to lumbar puncture expertise.
Moderate Rec High Evidence VALOR 2022Document the specific variant, zygosity, penetrance estimate, and family implications. Address the needs of asymptomatic at-risk relatives separately, with dedicated genetic counselling and clear boundaries about testing timelines.
Strong Rec Low Evidence EFNS 2012Multidisciplinary Clinic Care in ALS Management
The single most effective intervention in ALS management is referral to a specialist multidisciplinary clinic. Observational studies consistently report longer survival and better quality of life for patients attending these clinics, with benefits that appear driven by earlier non-invasive ventilation, timely gastrostomy, coordinated symptom management, and proactive advance care planning.
Refer every newly diagnosed patient to a specialist ALS multidisciplinary clinic. Key team members are neurology, respiratory medicine, speech and language therapy, dietetics, occupational and physical therapy, clinical nursing, social work, and palliative care.
Strong Rec High Evidence EFNS 2012 AAN 2009Document the ALSFRS-R score at every clinic visit. The slope of ALSFRS-R decline is a strong prognostic indicator and a useful tool for explaining rate of progression to patients and families.
Strong Rec Moderate Evidence EFNS 2012Assess for cognitive and behavioural impairment at baseline and at least annually. Use a screening tool validated for motor disease such as the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) — frontotemporal changes occur in up to half of patients and affect capacity for complex decisions.
Moderate Rec Moderate Evidence EFNS 2012Attend explicitly to caregiver burden. Carers of patients with ALS experience some of the highest burden scores reported in neurodegenerative disease; offer practical support, respite, and psychological care as active components of the overall plan.
Strong Rec Moderate Evidence AAN 2009Respiratory Surveillance and Support
Respiratory failure is the most common cause of death in ALS. Early identification of hypoventilation and timely non-invasive ventilation (NIV) are the two highest-yield interventions in the respiratory domain. NIV extends survival by roughly 7–10 months on average and improves sleep and quality of life.
Monitor respiratory function at every clinic visit (at least every 3 months). Use upright and supine FVC, sniff nasal inspiratory pressure (SNIP), and overnight oximetry with capnography when feasible. Symptom-based assessment alone misses meaningful hypoventilation.
Strong Rec Moderate Evidence EFNS 2012 AAN 2009Initiate non-invasive ventilation when FVC falls below 50% predicted, SNIP is below 40 cmH₂O, or the patient reports orthopnoea or symptoms of nocturnal hypoventilation — whichever comes first.
Strong Rec High Evidence EFNS 2012 AAN 2009Offer mechanical insufflation-exsufflation (cough assist) once peak cough flow falls below 270 L/min to clear secretions effectively and reduce hospitalisation for respiratory tract infection.
Moderate Rec Moderate Evidence AAN 2009Discuss tracheostomy ventilation proactively well before it becomes urgent. The decision is highly individual — some patients choose it and do well for years, others decline it firmly. The conversation should be documented in the advance care plan.
Strong Rec Low Evidence EFNS 2012Nutritional Support and Gastrostomy
Weight loss, dysphagia, and hypermetabolism together drive nutritional failure in ALS. Both the degree of weight loss and the timing of gastrostomy placement independently predict survival. Early dietetic engagement is therefore a central component, not an afterthought.
Weigh patients at every clinic visit and document weight trajectory. Initiate high-calorie supplementation when weight loss exceeds 5% of pre-illness baseline, and escalate dietetic input well before the 10% threshold.
Strong Rec Moderate Evidence EFNS 2012 AAN 2009Offer percutaneous gastrostomy while FVC remains above 50% predicted and before weight loss exceeds 10% of baseline. Procedure risk rises sharply once FVC falls below 50%, though radiologically inserted or per-oral techniques can still be considered with specialist input.
Strong Rec Moderate Evidence EFNS 2012Counsel patients that gastrostomy supports but does not replace oral intake when swallowing is safe. Many patients continue to eat modest amounts for pleasure long after the tube is placed.
Strong Rec Low Evidence EFNS 2012Clinical Decision Pathway
A practical, question-based approach to building a care plan for a newly diagnosed patient. Work through the questions in order from diagnosis to palliation.
Symptom Management and Palliative Care
Symptom management is where clinicians add the most visible value in ALS management. Focused, proactive attention to drooling, pseudobulbar affect, cramps, spasticity, pain, fatigue, and emotional distress makes a concrete difference at every stage of disease.
| Symptom | First-Line Option | Second-Line Option | Practical Tips |
|---|---|---|---|
| Sialorrhea | Glycopyrrolate or amitriptyline | Salivary gland botulinum toxin; parotid radiotherapy | Watch for anticholinergic load in older patients |
| Pseudobulbar affect | Dextromethorphan-quinidine | SSRI or SNRI | Distinguish from depression before treating |
| Cramps | Stretching, hydration | Mexiletine; levetiracetam | Quinine risks and limited availability make mexiletine the usual escalation |
| Spasticity | Baclofen; physical therapy | Tizanidine; botulinum toxin for focal spasticity | Titrate cautiously; excess dose can worsen weakness |
| Pain | Positioning, paracetamol, NSAID | Low-dose opioid; gabapentinoid for neuropathic features | Pain is underrecognised; ask at every visit |
| Air hunger and terminal distress | Low-dose opioid (oral morphine) | Benzodiazepine if anxiety prominent | Anticipatory prescribing in late stage; coordinate with community palliative care |
Evidence in Context
A brief map of the evidence base that shapes contemporary ALS management, where the frameworks agree, and where open questions remain.
Where the EFNS and AAN Frameworks Agree
Both EFNS and AAN strongly endorse riluzole for every patient, multidisciplinary clinic care, early non-invasive ventilation, proactive gastrostomy, cognitive screening, and integrated palliative care. They converge on the broad architecture of ALS management; differences are usually at the level of dose, timing, and specific trigger thresholds.
Diagnostic Frameworks: El Escorial, Awaji, Gold Coast
The original El Escorial criteria were designed for trial enrolment and prioritise specificity. The Awaji-shima modifications improve electrodiagnostic sensitivity by accepting fasciculations in a chronically denervated muscle. The newer Gold Coast criteria simplify the scheme further and are increasingly used in clinical practice and research. All three frameworks converge for established disease; their differences matter most in early or atypical presentations.
The Multidisciplinary Clinic Evidence
Multiple cohort and registry studies have shown that attendance at a specialist multidisciplinary clinic is associated with longer survival, more guideline-concordant care, and better quality of life, compared with general neurology follow-up. Randomised evidence is limited by the ethics of withholding multidisciplinary care, but the observational signal is consistent and large.
The Gene-Targeted Era
Tofersen established proof of concept for antisense therapy in ALS. Trials targeting C9orf72 and FUS variants are ongoing, and gene-targeted therapy is expected to expand over the next 5–10 years. This makes universal genetic counselling and testing a practical imperative, not a research niche.
Open Questions
Outstanding questions include the appropriate patient selection for edaravone in contemporary practice, the role of combination disease-modifying therapy, the use of neurofilament as an early marker of treatment response, and the ethics and logistics of pre-symptomatic genetic testing and treatment in high-penetrance variants.
References
- 1.Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) — revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–375. doi:10.1111/j.1468-1331.2011.03501.x
- 2.Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73(15):1218–1226. doi:10.1212/WNL.0b013e3181bc0141
- 3.de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497–503. doi:10.1016/j.clinph.2007.09.143
- 4.Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis. Lancet Neurol. 2017;16(7):505–512. doi:10.1016/S1474-4422(17)30115-1
- 5.Miller TM, Cudkowicz ME, Genge A, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (VALOR). N Engl J Med. 2022;387(12):1099–1110. doi:10.1056/NEJMoa2204705
How to Read the Evidence Tags
Every recommendation in this article carries two tags — for recommendation strength and evidence quality — along with a source tag. These are Medaptly’s own simplified interpretations, not reproductions of any guideline body’s classification system.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |